Amyotrophic Lateral Sclerosis Archives

FDA Advisory Panel Narrowly Votes Against New ALS Drug

April 19, 2022

In a close vote, an advisory panel for the US Food and Drug Administration decided not to recommend the approval of an experimental drug for amyotrophic lateral sclerosis (ALS).

Neurodegenerative Diseases

FDA Panel Votes on Fixed-Dose Combination Therapy for ALS

By

Diana Ernst, RPh

April 15, 2022

AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.

AAN 2022

GBA Variants Impact Cognitive Status in Amyotrophic Lateral Sclerosis

By

Brandon May

April 4, 2022

Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.

Neurodegenerative Diseases

Serum ADMA Level as a Prognostic Biomarker for Amyotrophic Lateral Sclerosis

By

Colby Stong

March 3, 2022

Researchers sought to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis, and to compare cerebrospinal fluid and serum ADMA levels with other ALS biomarkers.

Neurodegenerative Diseases

Incidence of Amyotrophic Lateral Sclerosis in the US About 1.6 Per 100,000 Population

By

Mary Stroka

February 14, 2022

Researchers sought to estimate incidence rates and case counts of amyotrophic lateral sclerosis in the US from 2014 through 2016 using administrative and self-reported databases.

Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis Risk Tied to NFL Play Duration in Athletes

By

Mary Stroka

February 7, 2022

Researcher sought to assess the incidence and mortality from ALS in NFL athletes and to describe the characteristics associated with ALS incidence in this cohort.

Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis Diet: The Tolerability of High-Caloric Food Supplements

By

Sheila Jacobs

February 4, 2022

Researchers sought to compare various high-caloric food supplements as add-on therapy to normal food intake and standard treatment in patients with ALS.

Neuromuscular Disorders

Amyotrophic Lateral Sclerosis Cognitive Profiles: Levels of Insight Into Behavioral Changes

By

Brandon May

January 24, 2022

Researchers sought to assess the loss of insight related to behavioral changes across cognitive profiles in amyotrophic lateral sclerosis subgroups.

Neurodegenerative Diseases

Fixed-Dose Combo Therapy for Amyotrophic Lateral Sclerosis Gets Priority Review

By

Diana Ernst, RPh

January 10, 2022

AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.

Seizures and epilepsy (≥2 unprovoked seizures) are more common in patients with APS compared with the general population.6,10 Between 3% and 10% of patients with APS have seizures/epilepsy, a prevalence that is 10 times greater than that of the general population.10 In half of these patients, epilepsy onset is after diagnosis.3 Epilepsy is more common in APS secondary to SLE vs primary APS (13.7% vs 6%; P <.05).11 Evidence of a correlation between aPL positivity and seizure is inconclusive.10 Seizures and epilepsy in patients with APS are primarily attributable to vascular disease.6 In a cohort study of 538 patients with APS, the odds ratio for epilepsy was 4.05 (95% CI, 2.05-8.00) in those with a prior central nervous system thromboembolic event.11 Epilepsy was also associated with higher rates of thrombocytopenia, livedo reticularis, and autoimmune hemolytic anemia.11 Some patients with APS with epilepsy have normal brain MRI results,3 and in vitro studies have implicated interactions between autoantibodies and neural structures.6

Neuromuscular Disorders

EEG Identifies Clinical Subgroups Within Amyotrophic Lateral Sclerosis

By

Colby Stong

December 21, 2021

Using similarity network fusion and spectral clustering, researchers sought to identify ALS disease subphenotypes and whether different patterns of disruption are predictive of outcome.